



US010226576B2

(12) **United States Patent**
Kiani

(10) **Patent No.:** **US 10,226,576 B2**
(45) **Date of Patent:** ***Mar. 12, 2019**

(54) **SEPSIS MONITOR**

(71) Applicant: **Masimo Corporation**, Irvine, CA (US)

(72) Inventor: **Massi E. Kiani**, Laguna Niguel, CA (US)

(73) Assignee: **Masimo Corporation**, Irvine, CA (US)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 474 days.

This patent is subject to a terminal disclaimer.

(21) Appl. No.: **14/191,925**

(22) Filed: **Feb. 27, 2014**

(65) **Prior Publication Data**

US 2014/0180038 A1 Jun. 26, 2014

Related U.S. Application Data

(63) Continuation-in-part of application No. 13/100,172, filed on May 3, 2011, now Pat. No. 8,663,107, which (Continued)

(51) **Int. Cl.**

A61B 7/00 (2006.01)
A61M 5/172 (2006.01)
A61B 5/0205 (2006.01)
A61B 5/022 (2006.01)
A61B 5/0245 (2006.01)
A61B 5/08 (2006.01)

(Continued)

(52) **U.S. Cl.**

CPC **A61M 5/1723** (2013.01); **A61B 5/022** (2013.01); **A61B 5/0205** (2013.01); **A61B 5/02455** (2013.01); **A61B 5/08** (2013.01);

A61B 5/14551 (2013.01); **A61B 5/412** (2013.01); **A61B 5/6826** (2013.01); **A61B 5/6838** (2013.01); **A61B 7/04** (2013.01); **A61B 5/082** (2013.01); **A61B 2560/0276** (2013.01)

(58) **Field of Classification Search**

CPC **A61B 5/0205**
See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

4,248,241 A * 2/1981 Tacchi **A61B 5/0002**
128/903

4,869,253 A 9/1989 Craig, Jr. et al.
(Continued)

OTHER PUBLICATIONS

Angus, D.C., MD, MPH, FCCM, et al., "Epidemiology of Severe Sepsis in the United States: Analysis of Incidence, Outcome, and Associated Cost of Care," *Critical Care Medicine*, vol. 29, No. 7, pp. 1303-1310.

(Continued)

Primary Examiner — Christopher D Koharski


Assistant Examiner — Amanda Steinberg

(74) *Attorney, Agent, or Firm* — Knobbe Martens Olson & Bear LLP

(57) **ABSTRACT**

Sensors are attached to a living being so as to generate corresponding sensor signals. A monitor is in communications with the sensors so as to derive physiological parameters responsive to the sensor signals. Predetermined limits are applied to the physiological parameters. At least one indicator responsive to the physiological parameters and the predetermined limits signal the onset of a sepsis condition in the living being.

4 Claims, 6 Drawing Sheets



Related U.S. Application Data

is a continuation of application No. 11/803,936, filed on May 15, 2007, now Pat. No. 7,941,199.

- (60) Provisional application No. 60/800,629, filed on May 15, 2006.

(51) **Int. Cl.**

A61B 5/1455 (2006.01)

A61B 5/00 (2006.01)

A61B 7/04 (2006.01)

(56) **References Cited**

U.S. PATENT DOCUMENTS

4,960,128 A	10/1990	Gordon et al.	6,110,522 A	8/2000	Lepper, Jr. et al.
4,964,408 A	10/1990	Hink et al.	6,124,597 A	9/2000	Shehada
5,041,187 A	8/1991	Hink et al.	6,128,521 A	10/2000	Marro et al.
5,069,213 A	12/1991	Polczynski	6,129,675 A	10/2000	Jay
5,163,438 A	11/1992	Gordon et al.	6,144,868 A	11/2000	Parker
5,319,355 A	6/1994	Russek	6,151,516 A	11/2000	Kiani-Azarbayjany et al.
5,337,744 A	8/1994	Branigan	6,152,754 A	11/2000	Gerhardt et al.
5,341,805 A	8/1994	Stavridi et al.	6,157,850 A	12/2000	Diab et al.
D353,195 S	12/1994	Savage et al.	6,165,005 A	12/2000	Mills et al.
D353,196 S	12/1994	Savage et al.	6,171,258 B1 *	1/2001	Karakasoglu A61B 5/0205
5,377,676 A	1/1995	Vari et al.			600/529
D359,546 S	6/1995	Savage et al.	6,184,521 B1	2/2001	Coffin, IV et al.
5,431,170 A	7/1995	Mathews	6,206,830 B1	3/2001	Diab et al.
D361,840 S	8/1995	Savage et al.	6,229,856 B1	5/2001	Diab et al.
D362,063 S	9/1995	Savage et al.	6,232,609 B1	5/2001	Snyder et al.
5,452,717 A	9/1995	Branigan et al.	6,236,872 B1	5/2001	Diab et al.
D363,120 S	10/1995	Savage et al.	6,241,683 B1	6/2001	Macklem et al.
5,456,252 A	10/1995	Vari et al.	6,253,097 B1	6/2001	Aronow et al.
5,479,934 A	1/1996	Imran	6,256,523 B1	7/2001	Diab et al.
5,482,036 A	1/1996	Diab et al.	6,263,222 B1	7/2001	Diab et al.
5,490,505 A	2/1996	Diab et al.	6,278,522 B1	8/2001	Lepper, Jr. et al.
5,494,043 A	2/1996	O'Sullivan et al.	6,280,213 B1	8/2001	Tobler et al.
5,533,511 A	7/1996	Kaspari et al.	6,285,896 B1	9/2001	Tobler et al.
5,534,851 A	7/1996	Russek	6,301,493 B1	10/2001	Marro et al.
5,561,275 A	10/1996	Savage et al.	6,308,089 B1	10/2001	von der Ruhr et al.
5,562,002 A	10/1996	Lalin	6,317,627 B1	11/2001	Ennen et al.
5,590,649 A	1/1997	Caro et al.	6,321,100 B1	11/2001	Parker
5,602,924 A	2/1997	Durand et al.	6,325,761 B1	12/2001	Jay
5,632,272 A	5/1997	Diab et al.	6,334,065 B1	12/2001	Al-Ali et al.
5,638,816 A	6/1997	Kiani-Azarbayjany et al.	6,343,224 B1	1/2002	Parker
5,638,818 A	6/1997	Diab et al.	6,349,228 B1	2/2002	Kiani et al.
5,645,440 A	7/1997	Tobler et al.	6,360,114 B1	3/2002	Diab et al.
5,685,299 A	11/1997	Diab et al.	6,368,283 B1	4/2002	Xu et al.
D393,830 S	4/1998	Tobler et al.	6,371,921 B1	4/2002	Caro et al.
5,743,262 A	4/1998	Lepper, Jr. et al.	6,377,829 B1	4/2002	Al-Ali
5,758,644 A	6/1998	Diab et al.	6,388,240 B2	5/2002	Schulz et al.
5,760,910 A	6/1998	Lepper, Jr. et al.	6,397,091 B2	5/2002	Diab et al.
5,769,785 A	6/1998	Diab et al.	6,430,437 B1	8/2002	Marro
5,782,757 A	7/1998	Diab et al.	6,430,525 B1	8/2002	Weber et al.
5,785,659 A	7/1998	Caro et al.	6,463,311 B1	10/2002	Diab
5,791,347 A	8/1998	Flaherty et al.	6,470,199 B1	10/2002	Kopotic et al.
5,810,734 A	9/1998	Caro et al.	6,501,975 B2	12/2002	Diab et al.
5,823,950 A	10/1998	Diab et al.	6,505,059 B1	1/2003	Kollias et al.
5,830,131 A	11/1998	Caro et al.	6,515,273 B2	2/2003	Al-Ali
5,833,618 A	11/1998	Caro et al.	6,519,487 B1	2/2003	Parker
5,860,919 A	1/1999	Kiani-Azarbayjany et al.	6,525,386 B1	2/2003	Mills et al.
5,890,929 A	4/1999	Mills et al.	6,526,300 B1	2/2003	Kiani et al.
5,904,654 A	5/1999	Wohlmann et al.	6,541,756 B2	4/2003	Schulz et al.
5,919,134 A	7/1999	Diab	6,542,764 B1	4/2003	Al-Ali et al.
5,934,925 A	8/1999	Tobler et al.	6,580,086 B1	6/2003	Schulz et al.
5,940,182 A	8/1999	Lepper, Jr. et al.	6,584,336 B1	6/2003	Ali et al.
5,995,855 A	11/1999	Kiani et al.	6,595,316 B2	7/2003	Cybulski et al.
5,997,343 A	12/1999	Mills et al.	6,597,932 B2	7/2003	Tian et al.
6,002,952 A	12/1999	Diab et al.	6,597,933 B2	7/2003	Kiani et al.
6,011,986 A	1/2000	Diab et al.	6,606,511 B1	8/2003	Ali et al.
6,027,452 A	2/2000	Flaherty et al.	6,632,181 B2	10/2003	Flaherty et al.
6,036,642 A	3/2000	Diab et al.	6,639,668 B1	10/2003	Trepagnier
6,045,509 A	4/2000	Caro et al.	6,640,116 B2	10/2003	Diab
6,067,462 A	5/2000	Diab et al.	6,643,530 B2	11/2003	Diab et al.
6,081,735 A	6/2000	Diab et al.	6,650,917 B2	11/2003	Diab et al.
6,088,607 A	7/2000	Diab et al.	6,654,624 B2	11/2003	Diab et al.
			6,658,276 B2	12/2003	Diab et al.
			6,661,161 B1	12/2003	Lanzo et al.
			6,671,531 B2	12/2003	Al-Ali et al.
			6,678,543 B2	1/2004	Diab et al.
			6,684,090 B2	1/2004	Ali et al.
			6,684,091 B2	1/2004	Parker
			6,697,656 B1	2/2004	Al-Ali
			6,697,657 B1	2/2004	Shehada et al.
			6,697,658 B2	2/2004	Al-Ali
			RE38,476 E	3/2004	Diab et al.
			6,699,194 B1	3/2004	Diab et al.
			6,714,804 B2	3/2004	Al-Ali et al.
			RE38,492 E	4/2004	Diab et al.
			6,721,582 B2	4/2004	Trepagnier et al.
			6,721,585 B1	4/2004	Parker
			6,725,075 B2	4/2004	Al-Ali
			6,728,560 B2	4/2004	Kollias et al.
			6,733,464 B2	5/2004	Olbrich et al.

(56)

References Cited

U.S. PATENT DOCUMENTS

6,735,459 B2	5/2004	Parker	7,341,559 B2	3/2008	Schulz et al.
6,745,060 B2	6/2004	Diab et al.	7,343,186 B2	3/2008	Lamego et al.
6,760,607 B2	7/2004	Al-Ali	D566,282 S	4/2008	Al-Ali et al.
6,770,028 B1	8/2004	Ali et al.	7,355,512 B1	4/2008	Al-Ali
6,771,994 B2	8/2004	Kiani et al.	7,356,365 B2	4/2008	Schurman
6,792,300 B1	9/2004	Diab et al.	7,371,981 B2	5/2008	Abdul-Hafiz
6,813,511 B2	11/2004	Diab et al.	7,373,193 B2	5/2008	Al-Ali et al.
6,816,741 B2	11/2004	Diab	7,373,194 B2	5/2008	Weber et al.
6,822,564 B2	11/2004	Al-Ali	7,376,453 B1	5/2008	Diab et al.
6,826,419 B2	11/2004	Diab et al.	7,377,794 B2	5/2008	Al Ali et al.
6,830,711 B2	12/2004	Mills et al.	7,377,899 B2	5/2008	Weber et al.
6,850,787 B2	2/2005	Weber et al.	7,383,070 B2	6/2008	Diab et al.
6,850,788 B2	2/2005	Al-Ali	7,415,297 B2	8/2008	Al-Ali et al.
6,852,083 B2	2/2005	Caro et al.	7,428,432 B2	9/2008	Ali et al.
6,860,266 B2	3/2005	Blike	7,438,683 B2	10/2008	Al-Ali et al.
6,861,639 B2	3/2005	Al-Ali	7,440,787 B2	10/2008	Diab
6,898,452 B2	5/2005	Al-Ali et al.	7,454,240 B2	11/2008	Diab et al.
6,920,345 B2	7/2005	Al-Ali et al.	7,467,002 B2	12/2008	Weber et al.
6,931,268 B1	8/2005	Kiani-Azarbayjany et al.	7,469,157 B2	12/2008	Diab et al.
6,934,570 B2	8/2005	Kiani et al.	7,471,969 B2	12/2008	Diab et al.
6,939,305 B2	9/2005	Flaherty et al.	7,471,971 B2	12/2008	Diab et al.
6,943,348 B1	9/2005	Coffin, IV	7,483,729 B2	1/2009	Al-Ali et al.
6,950,687 B2	9/2005	Al-Ali	7,483,730 B2	1/2009	Diab et al.
6,961,598 B2	11/2005	Diab	7,489,958 B2	2/2009	Diab et al.
6,970,792 B1	11/2005	Diab	7,496,391 B2	2/2009	Diab et al.
6,979,812 B2	12/2005	Al-Ali	7,496,393 B2	2/2009	Diab et al.
6,985,764 B2	1/2006	Mason et al.	D587,657 S	3/2009	Al-Ali et al.
6,993,371 B2	1/2006	Kiani et al.	7,499,741 B2	3/2009	Diab et al.
6,996,427 B2	2/2006	Ali et al.	7,499,835 B2	3/2009	Weber et al.
6,999,904 B2	2/2006	Weber et al.	7,500,950 B2	3/2009	Al-Ali et al.
7,003,338 B2	2/2006	Weber et al.	7,509,154 B2	3/2009	Diab et al.
7,003,339 B2	2/2006	Diab et al.	7,509,494 B2	3/2009	Al-Ali
7,015,451 B2	2/2006	Dalke et al.	7,510,849 B2	3/2009	Schurman et al.
7,024,233 B2	4/2006	Ali et al.	7,513,875 B2*	4/2009	Kushnir A61B 5/08 128/204.23
7,027,849 B2	4/2006	Al-Ali	7,526,328 B2	4/2009	Diab et al.
7,030,749 B2	4/2006	Al-Ali	7,530,942 B1	5/2009	Diab
7,034,692 B2	4/2006	Hickle	7,530,949 B2	5/2009	Al Ali et al.
7,039,449 B2	5/2006	Al-Ali	7,530,955 B2	5/2009	Diab et al.
7,041,060 B2	5/2006	Flaherty et al.	7,536,214 B2	5/2009	Myers et al.
7,044,918 B2	5/2006	Diab	7,563,110 B2	7/2009	Al-Ali et al.
7,048,687 B1	5/2006	Reuss et al.	7,596,398 B2	9/2009	Al-Ali et al.
7,067,893 B2	6/2006	Mills et al.	7,618,375 B2	11/2009	Flaherty
7,081,095 B2	7/2006	Lynn et al.	D606,659 S	12/2009	Kiani et al.
7,090,648 B2	8/2006	Sackner et al.	7,647,083 B2	1/2010	Al-Ali et al.
7,096,052 B2	8/2006	Mason et al.	D609,193 S	2/2010	Al-Ali et al.
7,096,054 B2	8/2006	Abdul-Hafiz et al.	7,668,579 B2	2/2010	Lynn
7,132,641 B2	11/2006	Schulz et al.	D614,305 S	4/2010	Al-Ali et al.
7,142,901 B2	11/2006	Kiani et al.	RE41,317 E	5/2010	Parker
7,149,561 B2	12/2006	Diab	7,729,733 B2	6/2010	Al-Ali et al.
7,186,966 B2	3/2007	Al-Ali	7,734,320 B2	6/2010	Al-Ali
7,190,261 B2	3/2007	Al-Ali	7,758,503 B2	7/2010	Lynn et al.
7,207,964 B2	4/2007	Davidner et al.	7,761,127 B2	7/2010	Al-Ali et al.
7,215,984 B2	5/2007	Diab	7,761,128 B2	7/2010	Al-Ali et al.
7,215,986 B2	5/2007	Diab	7,764,982 B2	7/2010	Dalke et al.
7,221,971 B2	5/2007	Diab	D621,516 S	8/2010	Kiani et al.
7,225,006 B2	5/2007	Al-Ali et al.	7,791,155 B2	9/2010	Diab
7,225,007 B2	5/2007	Al-Ali	7,801,581 B2	9/2010	Diab
RE39,672 E	6/2007	Shehada et al.	7,811,279 B2	10/2010	John
7,239,905 B2	7/2007	Kiani-Azarbayjany et al.	7,822,452 B2	10/2010	Schurman et al.
7,245,953 B1	7/2007	Parker	RE41,912 E	11/2010	Parker
7,252,637 B2	8/2007	Ebner et al.	7,844,313 B2	11/2010	Kiani et al.
7,254,429 B2	8/2007	Schurman et al.	7,844,314 B2	11/2010	Al-Ali
7,254,431 B2	8/2007	Al-Ali	7,844,315 B2	11/2010	Al-Ali
7,254,433 B2	8/2007	Diab et al.	7,865,222 B2	1/2011	Weber et al.
7,254,434 B2	8/2007	Schulz et al.	7,873,497 B2	1/2011	Weber et al.
7,272,425 B2	9/2007	Al-Ali	7,880,606 B2	2/2011	Al-Ali
7,274,955 B2	9/2007	Kiani et al.	7,880,626 B2	2/2011	Al-Ali et al.
D554,263 S	10/2007	Al-Ali	7,891,355 B2	2/2011	Al-Ali et al.
7,280,858 B2	10/2007	Al-Ali et al.	7,894,868 B2	2/2011	Al-Ali et al.
7,289,835 B2	10/2007	Mansfield et al.	7,899,507 B2	3/2011	Al-Ali et al.
7,292,883 B2	11/2007	De Felice et al.	7,899,518 B2	3/2011	Trepagnier et al.
7,295,866 B2	11/2007	Al-Ali	7,904,132 B2	3/2011	Weber et al.
7,328,053 B1	2/2008	Diab et al.	7,909,772 B2	3/2011	Popov et al.
7,332,784 B2	2/2008	Mills et al.	7,910,875 B2	3/2011	Al-Ali
7,340,287 B2	3/2008	Mason et al.	7,919,713 B2	4/2011	Al-Ali et al.
			7,937,128 B2	5/2011	Al-Ali
			7,937,129 B2	5/2011	Mason et al.
			7,937,130 B2	5/2011	Diab et al.

(56)

References Cited

U.S. PATENT DOCUMENTS

7,941,199 B2	5/2011	Kiani	8,430,817 B1	4/2013	Al-Ali et al.
7,951,086 B2	5/2011	Flaherty et al.	8,437,825 B2	5/2013	Dalvi et al.
7,957,780 B2	6/2011	Lamego et al.	8,455,290 B2	6/2013	Siskavich
7,962,188 B2	6/2011	Kiani et al.	8,457,703 B2	6/2013	Al-Ali
7,962,190 B1	6/2011	Diab et al.	8,457,707 B2	6/2013	Kiani
7,976,472 B2	7/2011	Kiani	8,463,349 B2	6/2013	Diab et al.
7,988,637 B2	8/2011	Diab	8,466,286 B2	6/2013	Bellot et al.
7,990,382 B2	8/2011	Kiani	8,471,713 B2	6/2013	Poeze et al.
7,991,446 B2	8/2011	Al-Ali et al.	8,473,020 B2	6/2013	Kiani et al.
8,000,761 B2	8/2011	Al-Ali	8,483,787 B2	7/2013	Al-Ali et al.
8,008,088 B2	8/2011	Bellott et al.	8,489,364 B2	7/2013	Weber et al.
RE42,753 E	9/2011	Kiani-Azarbayjany et al.	8,498,684 B2	7/2013	Weber et al.
8,019,400 B2	9/2011	Diab et al.	8,504,128 B2	8/2013	Blank et al.
8,028,701 B2	10/2011	Al-Ali et al.	8,509,867 B2	8/2013	Workman et al.
8,029,765 B2	10/2011	Bellott et al.	8,515,509 B2	8/2013	Bruinsma et al.
8,036,728 B2	10/2011	Diab et al.	8,523,781 B2	9/2013	Al-Ali
8,046,040 B2	10/2011	Ali et al.	8,529,301 B2	9/2013	Al-Ali et al.
8,046,041 B2	10/2011	Diab et al.	8,532,727 B2	9/2013	Ali et al.
8,046,042 B2	10/2011	Diab et al.	8,532,728 B2	9/2013	Diab et al.
8,048,040 B2	11/2011	Kiani	D692,145 S	10/2013	Al-Ali et al.
8,050,728 B2	11/2011	Al-Ali et al.	8,547,209 B2	10/2013	Kiani et al.
8,086,323 B2	12/2011	Reghabi et al.	8,548,548 B2	10/2013	Al-Ali
RE43,169 E	2/2012	Parker	8,548,549 B2	10/2013	Schurman et al.
8,118,620 B2	2/2012	Al-Ali et al.	8,548,550 B2	10/2013	Al-Ali et al.
8,126,528 B2	2/2012	Diab et al.	8,560,032 B2	10/2013	Al-Ali et al.
8,128,572 B2	3/2012	Diab et al.	8,560,034 B1	10/2013	Diab et al.
8,130,105 B2	3/2012	Al-Ali et al.	8,560,059 B2	10/2013	Hoarau et al.
8,145,287 B2	3/2012	Diab et al.	8,570,167 B2	10/2013	Al-Ali
8,150,487 B2	4/2012	Diab et al.	8,570,503 B2	10/2013	Vo et al.
8,175,672 B2	5/2012	Parker	8,571,617 B2	10/2013	Reichgott et al.
8,180,420 B2	5/2012	Diab et al.	8,571,618 B1	10/2013	Lamego et al.
8,182,443 B1	5/2012	Kiani	8,571,619 B2	10/2013	Al-Ali et al.
8,185,180 B2	5/2012	Diab et al.	8,577,431 B2	11/2013	Lamego et al.
8,190,223 B2	5/2012	Al-Ali et al.	8,581,732 B2	11/2013	Al-Ali et al.
8,190,227 B2	5/2012	Diab et al.	8,584,345 B2	11/2013	Al-Ali et al.
8,203,438 B2	6/2012	Kiani et al.	8,588,880 B2	11/2013	Abdul-Hafiz et al.
8,203,704 B2	6/2012	Merritt et al.	8,600,467 B2	12/2013	Al-Ali et al.
8,204,566 B2	6/2012	Schurman et al.	8,606,342 B2	12/2013	Diab
8,219,172 B2	7/2012	Schurman et al.	8,626,255 B2	1/2014	Al-Ali et al.
8,224,411 B2	7/2012	Al-Ali et al.	8,630,691 B2	1/2014	Lamego et al.
8,228,181 B2	7/2012	Al-Ali	8,634,889 B2	1/2014	Al-Ali et al.
8,229,533 B2	7/2012	Diab et al.	8,641,631 B2	2/2014	Sierra
8,233,955 B2	7/2012	Al-Ali et al.	8,652,060 B2	2/2014	Al-Ali
8,244,325 B2	8/2012	Al-Ali et al.	8,663,107 B2	3/2014	Kiani
8,255,026 B1	8/2012	Al-Ali	8,666,468 B1	3/2014	Al-Ali
8,255,027 B2	8/2012	Al-Ali et al.	8,667,967 B2	3/2014	Al-Ali et al.
8,255,028 B2	8/2012	Al-Ali et al.	8,670,811 B2	3/2014	O'Reilly
8,260,577 B2	9/2012	Weber et al.	8,670,814 B2	3/2014	Diab et al.
8,265,723 B1	9/2012	McHale et al.	8,676,286 B2	3/2014	Weber et al.
8,274,360 B2	9/2012	Sampath et al.	8,682,407 B2	3/2014	Al-Ali
8,280,473 B2	10/2012	Al-Ali	RE44,823 E	4/2014	Parker
8,301,217 B2	10/2012	Al-Ali et al.	RE44,875 E	4/2014	Kiani et al.
8,306,596 B2	11/2012	Schurman et al.	8,690,799 B2	4/2014	Telfort et al.
8,310,336 B2	11/2012	Muhsin et al.	8,700,112 B2	4/2014	Kiani
8,315,683 B2	11/2012	Al-Ali et al.	8,702,627 B2	4/2014	Telfort et al.
RE43,860 E	12/2012	Parker	8,706,179 B2	4/2014	Parker
8,335,550 B2	12/2012	Segman	8,712,494 B1	4/2014	MacNeish, III et al.
8,337,403 B2	12/2012	Al-Ali et al.	8,715,206 B2	5/2014	Telfort et al.
8,346,330 B2	1/2013	Lamego	8,718,735 B2	5/2014	Lamego et al.
8,353,842 B2	1/2013	Al-Ali et al.	8,718,737 B2	5/2014	Diab et al.
8,355,766 B2	1/2013	MacNeish, III et al.	8,718,738 B2	5/2014	Blank et al.
8,359,080 B2	1/2013	Diab et al.	8,720,249 B2	5/2014	Al-Ali
8,364,223 B2	1/2013	Al-Ali et al.	8,721,541 B2	5/2014	Al-Ali et al.
8,364,226 B2	1/2013	Diab et al.	8,721,542 B2	5/2014	Al-Ali et al.
8,374,665 B2	2/2013	Lamego	8,723,677 B1	5/2014	Kiani
8,385,995 B2	2/2013	Al-Ali et al.	8,740,792 B1	6/2014	Kiani et al.
8,385,996 B2	2/2013	Smith et al.	8,754,776 B2	6/2014	Poeze et al.
8,388,353 B2	3/2013	Kiani et al.	8,755,535 B2	6/2014	Telfort et al.
8,399,822 B2	3/2013	Al-Ali	8,755,856 B2	6/2014	Diab et al.
8,401,602 B2	3/2013	Kiani	8,755,872 B1	6/2014	Marinow
8,405,608 B2	3/2013	Al-Ali et al.	8,761,850 B2	6/2014	Lamego
8,414,499 B2	4/2013	Al-Ali et al.	8,764,671 B2	7/2014	Kiani
8,418,524 B2	4/2013	Al-Ali	8,768,423 B2	7/2014	Shakespeare et al.
8,423,106 B2	4/2013	Lamego et al.	8,771,204 B2	7/2014	Telfort et al.
8,428,967 B2	4/2013	Olsen et al.	8,777,634 B2	7/2014	Kiani et al.
			8,781,543 B2	7/2014	Diab et al.
			8,781,544 B2	7/2014	Al-Ali et al.
			8,781,549 B2	7/2014	Al-Ali et al.
			8,788,003 B2	7/2014	Schurman et al.

(56)

References Cited

U.S. PATENT DOCUMENTS

8,790,268	B2	7/2014	Al-Ali	9,267,572	B2	2/2016	Barker et al.
8,801,613	B2	8/2014	Al-Ali et al.	9,277,880	B2	3/2016	Poeze et al.
8,821,397	B2	9/2014	Al-Ali et al.	9,289,167	B2	3/2016	Diab et al.
8,821,415	B2	9/2014	Al-Ali et al.	9,295,421	B2	3/2016	Kiani et al.
8,830,449	B1	9/2014	Lamego et al.	9,307,928	B1	4/2016	Al-Ali et al.
8,831,700	B2	9/2014	Schurman et al.	9,323,894	B2	4/2016	Kiani
8,840,549	B2	9/2014	Al-Ali et al.	D755,392	S	5/2016	Hwang et al.
8,847,740	B2	9/2014	Kiani et al.	9,326,712	B1	5/2016	Kiani
8,849,365	B2	9/2014	Smith et al.	9,333,316	B2	5/2016	Kiani
8,852,094	B2	10/2014	Al-Ali et al.	9,339,220	B2	5/2016	Lamego et al.
8,852,994	B2	10/2014	Wojtczuk et al.	9,341,565	B2	5/2016	Lamego et al.
8,868,147	B2	10/2014	Stippick et al.	9,351,673	B2	5/2016	Diab et al.
8,868,150	B2	10/2014	Al-Ali et al.	9,351,675	B2	5/2016	Al-Ali et al.
8,870,792	B2	10/2014	Al-Ali et al.	9,364,181	B2	6/2016	Kiani et al.
8,886,271	B2	11/2014	Kiani et al.	9,368,671	B2	6/2016	Wojtczuk et al.
8,888,539	B2	11/2014	Al-Ali et al.	9,370,325	B2	6/2016	Al-Ali et al.
8,888,708	B2	11/2014	Diab et al.	9,370,326	B2	6/2016	McHale et al.
8,892,180	B2	11/2014	Weber et al.	9,370,335	B2	6/2016	Al-Ali et al.
8,897,847	B2	11/2014	Al-Ali	9,375,185	B2	6/2016	Ali et al.
8,909,310	B2	12/2014	Lamego et al.	9,386,953	B2	7/2016	Al-Ali
8,911,377	B2	12/2014	Al-Ali	9,386,961	B2	7/2016	Al-Ali et al.
8,912,909	B2	12/2014	Al-Ali et al.	9,392,945	B2	7/2016	Al-Ali et al.
8,920,317	B2	12/2014	Al-Ali et al.	9,397,448	B2	7/2016	Al-Ali et al.
8,921,699	B2	12/2014	Al-Ali et al.	9,408,542	B1	8/2016	Kinast et al.
8,922,382	B2	12/2014	Al-Ali et al.	9,436,645	B2	9/2016	Al-Ali et al.
8,929,964	B2	1/2015	Al-Ali et al.	9,445,759	B1	9/2016	Lamego et al.
8,942,777	B2	1/2015	Diab et al.	9,466,919	B2	10/2016	Kiani et al.
8,948,834	B2	2/2015	Diab et al.	9,474,474	B2	10/2016	Lamego et al.
8,948,835	B2	2/2015	Diab	9,480,422	B2	11/2016	Al-Ali
8,965,471	B2	2/2015	Lamego	9,480,435	B2	11/2016	Olsen
8,983,564	B2	3/2015	Al-Ali	9,492,110	B2	11/2016	Al-Ali et al.
8,989,831	B2	3/2015	Al-Ali et al.	9,510,779	B2	12/2016	Poeze et al.
8,996,085	B2	3/2015	Kiani et al.	9,517,024	B2	12/2016	Kiani et al.
8,998,809	B2	4/2015	Kiani	9,532,722	B2	1/2017	Lamego et al.
9,028,429	B2	5/2015	Telfort et al.	9,538,949	B2	1/2017	Al-Ali et al.
9,037,207	B2	5/2015	Al-Ali et al.	9,538,980	B2	1/2017	Telfort et al.
9,060,721	B2	6/2015	Reichgott et al.	9,549,696	B2	1/2017	Lamego et al.
9,066,666	B2	6/2015	Kiani	9,554,737	B2	1/2017	Schurman et al.
9,066,680	B1	6/2015	Al-Ali et al.	9,560,996	B2	2/2017	Kiani
9,072,474	B2	7/2015	Al-Ali et al.	9,560,998	B2	2/2017	Al-Ali et al.
9,078,560	B2	7/2015	Schurman et al.	9,566,019	B2	2/2017	Al-Ali et al.
9,084,569	B2	7/2015	Weber et al.	9,579,039	B2	2/2017	Jansen et al.
9,095,316	B2	8/2015	Welch et al.	9,591,975	B2	3/2017	Dalvi et al.
9,106,038	B2	8/2015	Telfort et al.	9,622,692	B2	4/2017	Lamego et al.
9,107,625	B2	8/2015	Telfort et al.	9,622,693	B2	4/2017	Diab
9,107,626	B2	8/2015	Al-Ali et al.	D788,312	S	5/2017	Al-Ali et al.
9,113,831	B2	8/2015	Al-Ali	9,636,055	B2	5/2017	Al-Ali et al.
9,113,832	B2	8/2015	Al-Ali	9,636,056	B2	5/2017	Al-Ali
9,119,595	B2	9/2015	Lamego	9,649,054	B2	5/2017	Lamego et al.
9,131,881	B2	9/2015	Diab et al.	9,662,052	B2	5/2017	Al-Ali et al.
9,131,882	B2	9/2015	Al-Ali et al.	9,668,679	B2	6/2017	Schurman et al.
9,131,883	B2	9/2015	Al-Ali	9,668,680	B2	6/2017	Bruinsma et al.
9,131,917	B2	9/2015	Telfort et al.	9,668,703	B2	6/2017	Al-Ali
9,138,180	B1	9/2015	Coverston et al.	9,675,286	B2	6/2017	Diab
9,138,182	B2	9/2015	Al-Ali et al.	9,687,160	B2	6/2017	Kiani
9,138,192	B2	9/2015	Weber et al.	9,693,719	B2	7/2017	Al-Ali et al.
9,142,117	B2	9/2015	Muhsin et al.	9,693,737	B2	7/2017	Al-Ali
9,153,112	B1	10/2015	Kiani et al.	9,697,928	B2	7/2017	Al-Ali et al.
9,153,121	B2	10/2015	Kiani et al.	9,717,425	B2	8/2017	Kiani et al.
9,161,696	B2	10/2015	Al-Ali et al.	9,717,458	B2	8/2017	Lamego et al.
9,161,713	B2	10/2015	Al-Ali et al.	9,724,016	B1	8/2017	Al-Ali et al.
9,167,995	B2	10/2015	Lamego et al.	9,724,024	B2	8/2017	Al-Ali
9,176,141	B2	11/2015	Al-Ali et al.	9,724,025	B1	8/2017	Kiani et al.
9,186,102	B2	11/2015	Bruinsma et al.	9,730,640	B2	8/2017	Diab et al.
9,192,312	B2	11/2015	Al-Ali	9,743,887	B2	8/2017	Al-Ali et al.
9,192,329	B2	11/2015	Al-Ali	9,749,232	B2	8/2017	Sampath et al.
9,192,351	B1	11/2015	Telfort et al.	9,750,442	B2	9/2017	Olsen
9,195,385	B2	11/2015	Al-Ali et al.	9,750,443	B2	9/2017	Smith et al.
9,211,072	B2	12/2015	Kiani	9,750,461	B1	9/2017	Telfort
9,211,095	B1	12/2015	Al-Ali	9,775,545	B2	10/2017	Al-Ali et al.
9,218,454	B2	12/2015	Kiani et al.	9,775,546	B2	10/2017	Diab et al.
9,226,696	B2	1/2016	Kiani	9,775,570	B2	10/2017	Al-Ali
9,241,662	B2	1/2016	Al-Ali et al.	9,778,079	B1	10/2017	Al-Ali et al.
9,245,668	B1	1/2016	Vo et al.	9,782,077	B2	10/2017	Lamego et al.
9,259,185	B2	2/2016	Abdul-Hafiz et al.	9,782,110	B2	10/2017	Kiani
				9,787,568	B2	10/2017	Lamego et al.
				9,788,735	B2	10/2017	Al-Ali
				9,788,768	B2	10/2017	Al-Ali et al.
				9,795,300	B2	10/2017	Al-Ali

(56)

References Cited

U.S. PATENT DOCUMENTS

9,795,310 B2	10/2017	Al-Ali		2014/0275808 A1	9/2014	Poeze et al.
9,795,358 B2	10/2017	Telfort et al.		2014/0275835 A1	9/2014	Lamego et al.
9,795,739 B2	10/2017	Al-Ali et al.		2014/0275871 A1	9/2014	Lamego et al.
2002/0103454 A1*	8/2002	Sackner	A61H 1/001	2014/0275872 A1	9/2014	Merritt et al.
			604/19	2014/0276115 A1	9/2014	Dalvi et al.
2003/0120182 A1*	6/2003	Wilkinson	A61B 5/08	2014/0288400 A1	9/2014	Diab et al.
			600/587	2014/0316217 A1	10/2014	Purdon et al.
2003/0208113 A1	11/2003	Mault et al.		2014/0316218 A1	10/2014	Purdon et al.
2004/0039295 A1	2/2004	Olbrich et al.		2014/0316228 A1	10/2014	Blank et al.
2004/0078219 A1	4/2004	Kaylor et al.		2014/0323825 A1	10/2014	Al-Ali et al.
2004/0236229 A1	11/2004	Freeman et al.		2014/0323897 A1	10/2014	Brown et al.
2005/0001728 A1	1/2005	Appelt et al.		2014/0323898 A1	10/2014	Purdon et al.
2005/0054942 A1	3/2005	Melker et al.		2014/0330092 A1	11/2014	Al-Ali et al.
2005/0148832 A1	7/2005	Reghabi et al.		2014/0330098 A1	11/2014	Merritt et al.
2005/0288571 A1	12/2005	Perkins et al.		2014/0336481 A1	11/2014	Shakespeare et al.
2006/0020179 A1	1/2006	Anderson et al.		2014/0357966 A1	12/2014	Al-Ali et al.
2006/0161054 A1	7/2006	Reuss et al.		2015/0005600 A1	1/2015	Blank et al.
2007/0024946 A1	2/2007	Panasyuk et al.		2015/0011907 A1	1/2015	Purdon et al.
2007/0032733 A1	2/2007	Burton		2015/0012231 A1	1/2015	Poeze et al.
2007/0100213 A1	5/2007	Dossas et al.		2015/0032029 A1	1/2015	Al-Ali et al.
2007/0129647 A1	6/2007	Lynn		2015/0038859 A1	2/2015	Dalvi et al.
2007/0191697 A1	8/2007	Lynn et al.		2015/0045637 A1	2/2015	Dalvi
2007/0219434 A1	9/2007	Abreu		2015/0080754 A1	3/2015	Purdon et al.
2007/0282478 A1	12/2007	Al-Ali et al.		2015/0087936 A1	3/2015	Al-Ali et al.
2008/0051764 A1	2/2008	Dent et al.		2015/0094546 A1	4/2015	Al-Ali
2008/0286763 A1	11/2008	Russwurm et al.		2015/0097701 A1	4/2015	Al-Ali et al.
2008/0306353 A1	12/2008	Douglas et al.		2015/0099950 A1	4/2015	Al-Ali et al.
2009/0069642 A1	3/2009	Gao et al.		2015/0099951 A1	4/2015	Al-Ali et al.
2009/0247984 A1	10/2009	Lamego et al.		2015/0099955 A1	4/2015	Al-Ali et al.
2009/0275813 A1	11/2009	Davis		2015/0101844 A1	4/2015	Al-Ali et al.
2009/0275844 A1	11/2009	Al-Ali		2015/0106121 A1	4/2015	Muhsin et al.
2010/0004518 A1	1/2010	Vo et al.		2015/0112151 A1	4/2015	Muhsin et al.
2010/0030040 A1	2/2010	Poeze et al.		2015/0116076 A1	4/2015	Al-Ali et al.
2011/0082711 A1	4/2011	Poeze et al.		2015/0126830 A1	5/2015	Schurman et al.
2011/0105854 A1	5/2011	Kiani et al.		2015/0141781 A1	5/2015	Weber et al.
2011/0125060 A1	5/2011	Telfort et al.		2015/0165312 A1	6/2015	Kiani
2011/0208015 A1	8/2011	Welch et al.		2015/0196237 A1	7/2015	Lamego
2011/0230733 A1	9/2011	Al-Ali		2015/0196249 A1	7/2015	Brown et al.
2011/0237969 A1	9/2011	Eckerbom et al.		2015/0216459 A1	8/2015	Al-Ali et al.
2012/0046557 A1	2/2012	Kiani		2015/0230755 A1	8/2015	Al-Ali et al.
2012/0165629 A1	6/2012	Merritt et al.		2015/0238722 A1	8/2015	Al-Ali
2012/0209082 A1	8/2012	Al-Ali		2015/0245773 A1	9/2015	Lamego et al.
2012/0209084 A1	8/2012	Olsen et al.		2015/0245794 A1	9/2015	Al-Ali
2012/0283524 A1	11/2012	Kiani et al.		2015/0257689 A1	9/2015	Al-Ali et al.
2012/0319816 A1	12/2012	Al-Ali		2015/0272514 A1	10/2015	Kiani et al.
2013/0023775 A1	1/2013	Lamego et al.		2015/0351697 A1	12/2015	Weber et al.
2013/0041591 A1	2/2013	Lamego		2015/0351704 A1	12/2015	Kiani et al.
2013/0060147 A1	3/2013	Welch et al.		2015/0359429 A1	12/2015	Al-Ali et al.
2013/0096405 A1	4/2013	Garfio		2015/0366472 A1	12/2015	Kiani
2013/0096936 A1	4/2013	Sampath et al.		2015/0366507 A1	12/2015	Blank
2013/0243021 A1	9/2013	Siskavich		2015/0380875 A1	12/2015	Coverston et al.
2013/0253334 A1	9/2013	Al-Ali et al.		2016/0007930 A1	1/2016	Weber et al.
2013/0267804 A1	10/2013	Al-Ali		2016/0029932 A1	2/2016	Al-Ali
2013/0296672 A1	11/2013	O'Neil et al.		2016/0051205 A1	2/2016	Al-Ali et al.
2013/0296713 A1	11/2013	Al-Ali et al.		2016/0058347 A1	3/2016	Reichgott et al.
2013/0324808 A1	12/2013	Al-Ali et al.		2016/0066823 A1	3/2016	Al-Ali et al.
2013/0331660 A1	12/2013	Al-Ali et al.		2016/0066824 A1	3/2016	Al-Ali et al.
2014/0012100 A1	1/2014	Al-Ali et al.		2016/0072429 A1	3/2016	Kiani et al.
2014/0051953 A1	2/2014	Lamego et al.		2016/0081552 A1	3/2016	Wojtczuk et al.
2014/0081100 A1	3/2014	Muhsin et al.		2016/0095543 A1	4/2016	Telfort et al.
2014/0081175 A1	3/2014	Telfort		2016/0095548 A1	4/2016	Al-Ali et al.
2014/0120564 A1	5/2014	Workman et al.		2016/0103598 A1	4/2016	Al-Ali et al.
2014/0121482 A1	5/2014	Merritt et al.		2016/0143548 A1	5/2016	Al-Ali
2014/0127137 A1	5/2014	Bellott et al.		2016/0166182 A1	6/2016	Al-Ali et al.
2014/0135588 A1	5/2014	Al-Ali et al.		2016/0166183 A1	6/2016	Poeze et al.
2014/0163344 A1	6/2014	Al-Ali		2016/0192869 A1	7/2016	Kiani et al.
2014/0163402 A1	6/2014	Lamego et al.		2016/0196388 A1	7/2016	Lamego
2014/0166076 A1	6/2014	Kiani et al.		2016/0197436 A1	7/2016	Barker et al.
2014/0171763 A1	6/2014	Diab		2016/0213281 A1	7/2016	Eckerbom et al.
2014/0180038 A1	6/2014	Kiani		2016/0228043 A1	8/2016	O'Neil et al.
2014/0180154 A1	6/2014	Sierra et al.		2016/0233632 A1	8/2016	Scruggs et al.
2014/0180160 A1	6/2014	Brown et al.		2016/0234944 A1	8/2016	Schmidt et al.
2014/0187973 A1	7/2014	Brown et al.		2016/0270735 A1	9/2016	Diab et al.
2014/0213864 A1	7/2014	Abdul-Hafiz et al.		2016/0283665 A1	9/2016	Sampath et al.
2014/0266790 A1	9/2014	Al-Ali et al.		2016/0287090 A1	10/2016	Al-Ali et al.
				2016/0287786 A1	10/2016	Kiani
				2016/0296169 A1	10/2016	McHale et al.
				2016/0310052 A1	10/2016	Al-Ali et al.
				2016/0314260 A1	10/2016	Kiani

(56)

References Cited

U.S. PATENT DOCUMENTS

2016/0324486 A1 11/2016 Al-Ali et al.
 2016/0324488 A1 11/2016 Olsen
 2016/0327984 A1 11/2016 Al-Ali et al.
 2016/0328528 A1 11/2016 Al-Ali et al.
 2016/0331332 A1 11/2016 Al-Ali
 2016/0367173 A1 12/2016 Dalvi et al.
 2017/0000394 A1 1/2017 Al-Ali et al.
 2017/0007134 A1 1/2017 Al-Ali et al.
 2017/0007190 A1 1/2017 Al-Ali et al.
 2017/0007198 A1 1/2017 Al-Ali et al.
 2017/0014083 A1 1/2017 Diab et al.
 2017/0014084 A1 1/2017 Al-Ali et al.
 2017/0027456 A1 2/2017 Kinast et al.
 2017/0042488 A1 2/2017 Muhsin
 2017/0055847 A1 3/2017 Kiani et al.
 2017/0055851 A1 3/2017 Al-Ali
 2017/0055882 A1 3/2017 Al-Ali et al.
 2017/0055887 A1 3/2017 Al-Ali
 2017/0055896 A1 3/2017 Al-Ali et al.
 2017/0079594 A1 3/2017 Telfort et al.
 2017/0086723 A1 3/2017 Al-Ali et al.
 2017/0143281 A1 5/2017 Olsen
 2017/0147774 A1 5/2017 Kiani
 2017/0156620 A1 6/2017 Al-Ali et al.
 2017/0173632 A1 6/2017 Al-Ali
 2017/0187146 A1 6/2017 Kiani et al.
 2017/0188919 A1 7/2017 Al-Ali et al.

2017/0196464 A1 7/2017 Jansen et al.
 2017/0196470 A1 7/2017 Lamego et al.
 2017/0202490 A1 7/2017 Al-Ali et al.
 2017/0224231 A1 8/2017 Al-Ali
 2017/0224233 A1 8/2017 Al-Ali
 2017/0224262 A1 8/2017 Al-Ali
 2017/0228516 A1 8/2017 Sampath et al.
 2017/0245790 A1 8/2017 Al-Ali et al.
 2017/0251974 A1 9/2017 Shreim et al.
 2017/0251975 A1 9/2017 Shreim et al.
 2017/0258403 A1 9/2017 Abdul-Hafiz et al.

OTHER PUBLICATIONS

Masimo, "SpCO™ Pulse CO-Oximetry™", pp. 1-4 (2005).
 Ohashi, K., et al., "Elevated Methemoglobin in Patients with Sepsis," *ACTA Anaesthesiologica Scandinavica*, 42, pp. 713-716 (1998).
www.ccmjournal.com/pt/re/ccm/fulltext.00003246-199806000-00019.htm?sessionid=, "Septic Shock: An Analysis of Outcomes for Patients with Onset on Hospital Wards Versus Intensive Care Units," *Critical Care Medicine*, vol. 26(6), 9 pages (Jun. 1998), downloaded and printed from the World Wide Web on Feb. 1, 2006.
<http://www.ispub.com/ostia/index.php?xmlFilePath=journals/ijpn/vol2n2/sepsis.xml>, "Plasma Carbon Monoxide Levels in Pediatrics Sepsis Syndrome," *The Internet Journal of Pediatrics and Neonatology*, vol. 2, No. 2, 11 pages (2002), downloaded and printed from the World Wide Web on Oct. 14, 2005.

* cited by examiner




FIG. 1




FIG. 2A




FIG. 2B




FIG. 3




FIG. 4




FIG. 5

SEPSIS MONITOR

CROSS-REFERENCE TO RELATED APPLICATIONS

The present application claims priority benefit under 35 U.S.C. § 120 to, and is a continuation of U.S. patent application Ser. No. 13/100172, filed May 3, 2011 entitled "Sepsis Monitor," which claims priority benefit under 35 U.S.C. § 120 to, and is a continuation of U.S. patent application Ser. No. 11/803,936, filed May 15, 2007, now U.S. Pat. No. 7,941,199, entitled "Sepsis Monitor," which claims priority benefit under 35 U.S.C. § 119(e) from U.S. Provisional Application No. 60/800,629, filed May 15, 2006, entitled "Septic Shock Monitor." The present application also incorporates the foregoing disclosures herein by reference.

BACKGROUND OF THE INVENTION

Sepsis is a serious medical condition caused by the body's response to an infection. The source of the infection can be any of a number of places throughout the body. Bacterial infections are the most common cause of sepsis, but sepsis can also be caused by fungal, parasitic, or viral infections. Toxins produced by an untreated or inadequately treated infection circulate in the bloodstream causing damage, for example, to the brain, heart, lungs, kidneys and liver. Severe sepsis can result in septic shock, a medical emergency in which the organs and tissues of the body are not receiving an adequate flow of blood.

SUMMARY OF THE INVENTION

The signs and symptoms of sepsis may be subtle. The unacceptably low survival rate of severe sepsis indicates that current patient identification strategies may be lacking. For example, conventional patient monitors give insufficient advance warning of deteriorating patient health or the onset of potentially serious physiological conditions resulting from sepsis. Advantageously, a sepsis monitor noninvasively measures patient condition so as to provide caregivers with an advanced warning or prediction of the onset sepsis. A sepsis monitor may also be configured to provide automatic intervention or treatment of sepsis.

SIRS (systemic inflammatory response syndrome) refers to the systemic activation of the body's immune response, such as from sepsis. SIRS is manifested by, for example, the presence of more than one of a temperature greater than 38° C. or less than 36° C.; a heart rate greater than 90 beats/min.; and a respiration rate greater than 20 breaths/min. Thus, in an embodiment, a sepsis monitor is responsive to more than one of pulse rate, respiration rate and temperature.

Sepsis also results in large amounts of nitrous oxide (NO) released into the blood. It has been shown that NO functions, in part, as a killer molecule that is activated by immune cells. The overproduction of NO during sepsis induces excessive vascular relaxation and a profound hypotension that is also a characteristic feature of sepsis. NO interacts rapidly with hemoglobin to form methemoglobin (HbMet). Thus, HbMet can function as a marker for NO generation in patients with sepsis. Further, endogenously produced CO functions as a messenger molecule as part of a complex cascade of mediators resulting from sepsis. A portion of the endogenous CO is exhaled and a portion is present as carboxyhemoglobin

(HbCO). Thus, in an embodiment, a sepsis monitor is responsive to one or more of HbCO, HbMet and blood pressure.

In an embodiment, sepsis monitoring is based upon one or more physiological parameters and associated parameter limits, trends, patterns and variability, alone or in combination. The physiological parameters may include: blood parameters derived from an optical sensor including one or more of oxygen saturation (SpO₂), pulse rate, HbCO and HbMet; respiration rate (RR) derived from an acoustic sensor or a capnography sensor, as examples; noninvasive blood pressure (NIBP) derived from a blood pressure sensor, such as an inflatable cuff and corresponding acoustic sensor, a continuous NIBP (CNIBP) measurement device or an intelligent cuff inflation (ICI) device, to name a few; and temperature manually measured or derived from a thermistor or other temperature transducer.

One aspect of a sepsis monitor is sensors attached to a living being so as to generate corresponding sensor signals. A monitor is in communications with the sensors so as to derive physiological parameters responsive to the sensor signals. Predetermined limits are applied to the physiological parameters. At least one indicator responsive to the physiological parameters and the predetermined limits signal the onset of a sepsis condition in the living being.

Another aspect of a sepsis monitor is identifying physiological parameters indicative of an onset of a sepsis condition in a living being. Sensor signals are generated that are responsive to the physiological parameters. The physiological parameters are computed from the sensor signals. Predetermined rules are applied to the physiological parameters so as to determine the onset of the sepsis condition. An indicator signals the potential existence and likely nonexistence of the sepsis condition.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 is a general block diagram of a sepsis monitoring system;

FIGS. 2A-B are detailed diagrams of sepsis monitoring system embodiments;

FIG. 3 is an illustration of a sepsis monitoring system embodiment;

FIG. 4 is a general block diagram of a sepsis monitor incorporating a multiple parameter processor; and

FIG. 5 is a detailed block diagram of a multiple parameter processor embodiment.

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENT

FIG. 1 illustrates a sepsis monitoring system **100** having one or more sensors **106** generating sensor signals **107** in response to physiological states of a living being, such as a patient **1**. A sepsis monitor **400** processes the sensor signals **107** and generates sepsis indicators **102** or intervention controls **103** or both, in response. In an open-loop configuration, one or more sepsis indicators **102** are observed by a caregiver **2**, who administers treatment in response. Alternatively, or in addition, the caregiver **2** initiates, pauses, halts or adjusts the settings of a sepsis treatment device **104** in response to the sepsis indicators **102**. In an embodiment, the sepsis indicators **102** signal one or more of a prediction of the onset of sepsis, a sepsis condition, a prediction of the onset of septic shock and a septic shock condition. In a closed-loop configuration, the sepsis treatment device **104** is responsive to one or more intervention controls **103** so as to

affect the treatment of the patient **1**, including, for example, initiating, pausing, halting or adjusting the dosage of administered drugs. In an embodiment, the intervention controls **103** are responsive to one or more of a prediction of the onset of sepsis, a sepsis condition, a prediction of the onset of septic shock and a septic shock condition.

As shown in FIG. 1, the sepsis treatment device **104** may be a drug infusion device, a medical gas inhalation device or a ventilation device to name a few. Drug infusion device and gas inhalation device control is described in U.S. patent application Ser. No. 11/654,904, filed Jan. 17, 2007, entitled Drug Administration Controller and incorporated by reference herein. Closed loop respirator control is described in U.S. patent application Ser. No. 11/585,678, filed Oct. 23, 2006, entitled Robust Ventilator Control and incorporated by reference herein.

As shown in FIG. 1, sensors **106** provide noninvasive measurements and include, for example, an optical sensor attached to a tissue site, such as a fingertip, for measuring one or more blood parameters. Noninvasive sensors **106** may also include acoustic sensors, blood pressure cuffs, ECG or EEG electrodes, CO₂ measuring capnography sensors and temperature sensors to name but a few. The sepsis monitor **400** is responsive to sensors signals **107** so as to generate parameter measurements, which may include SpO₂, pulse rate, perfusion index, perfusion variability index, HbCO, HbMet, total hemoglobin, fractional saturation, glucose, cyanide, respiration rate, blood pressure, CO₂, bilirubin, lung volume, cardiac output, temperature, consciousness and hydration measures, among other parameters. Such parameters may be measured intermittently or continuously. Although sensors **106** are described above with respect to noninvasive technologies, sensors **106** may be invasive or noninvasive. Invasive measurements may require a person to prepare a blood or tissue sample, which is then processed by an instrument or testing device, with the result read from the instrument or device and manually entered into the sepsis monitor **400**.

The sepsis monitor **400** may be a single instrument incorporating various hardware, software, circuits and code for processing sensor signals, deriving physiological parameters and processing those parameters to generate the indicators and controls described above. Alternatively, the sepsis monitor **400** may integrate one or more standalone instruments or plug-ins, each of which process specific sensor signals and derive particular physiological parameters. These may include blood parameter monitors, respiration rate monitors, blood pressure monitors, ECG and EEG monitors and capnometers, as a few examples.

In an embodiment, sensors **106** include a multiple wavelength optical sensor, such as described in U.S. patent application Ser. No. 11/376,013, filed Mar. 1, 2006 and entitled Multiple Wavelength Sensor Emitters; and the sepsis monitor **400** incorporates a patient monitor, such as described in U.S. patent application Ser. 11/367,033, filed Mar. 1, 2006 and entitled Noninvasive Multi-Parameter Patient Monitor, both patent applications assigned to Masimo Laboratories, Irvine, Calif. and both incorporated by reference herein.

In an embodiment, sensors **106** and measurement devices **108** include multiple wavelength sensors and corresponding noninvasive blood parameter monitors, such as Rainbow™ adhesive and reusable sensors and RAD-57™ and Radical-7™ monitors for measuring SpO₂, pulse rate, perfusion index, signal quality, HbCO and HbMet among other parameters. The Rainbow™ sensors and RAD-57™ and Radical-7™ monitors are available from Masimo Corporation,

Irvine, Calif. In an embodiment, sensors **106** include a pulse oximetry sensor, such as described in U.S. Pat. No. 5,782,757 entitled Low Noise Optical Probes and the sepsis monitor **400** incorporates a pulse oximeter, such as described in U.S. Pat. No. 5,632,272 entitled Signal Processing Apparatus, both assigned to Masimo Corporation, Irvine, Calif. and both incorporated by reference herein. In other embodiments, sensors **106** also include any of LNOP® adhesive or reusable sensors, SoftTouch™ sensors, Hi-Fi Trauma™ or Blue™ sensor all available from Masimo Corporation, Irvine, Calif. Further, the sepsis monitor **400** may also include any of Radical®, SatShare™, Rad-9™, Rad-5™, Rad-5v™ or PPO+™ Masimo SET® pulse oximeters all available from Masimo Corporation, Irvine, Calif.

In another embodiment, the sepsis monitor **400** and the sepsis treatment device **104** are incorporated within a single unit. For example, the sepsis monitor **400** and treatment device **104** may be incorporated within a single housing, or the devices may be separately housed but physically and proximately connected.

FIGS. 2A-B illustrate sepsis monitoring system embodiments **200**, **205**. As shown in FIG. 2A with respect to a system embodiment **200**, a sepsis monitor **400** is in communications with an optical sensor **210** and an acoustic sensor **220** attached to a patient **1**. An optical sensor processor **230** generates pulsatile-blood related parameters, such as pulse rate (PR) **234**, in response to optical sensor signals **212**. An acoustic sensor processor **240** generates body-sound related parameters **244**, such as respiration rate (RR), in response to acoustic sensor signals **222**. A temperature parameter **295** is generated via a temperature sensor or manually entered. A multiple parameter processor **500** processes the parameter measurements **234**, **244**, **295** alone or in combination and generates sepsis indicators and alarms **254** or drug administration controls **256**, or both, in response. An acoustic sensor is described in U.S. Pat. No. 6,661,161 entitled Piezoelectric Biological Sound Monitor with Printed Circuit Board and a corresponding respirator rate monitor is described in International App. No. PCT/CA2005/000536 and PUb. No. WO 2005/096931, filed Apr. 8, 2005, both applications incorporated by reference herein.

As shown in FIG. 2B with respect to a system embodiment **205**, a sepsis monitor **400** is in communications with an optical sensor **210** and a NIBP sensor **260** attached to a patient **1**. An optical sensor processor **230** generates pulsatile-blood related parameters, such as such as HbCO **236** and HbMet **238** in response to optical sensor signals **212**. An NIBP processor **270** generates blood pressure (BP) parameters, in response to NIBP sensor signals **262**. A multiple parameter processor **500** processes the parameter measurements **236**, **238**, **274** alone or in combination and generates sepsis indicators and alarms **254** or drug administration controls **256**, or both, in response. A continuous NIBP (CNIBP) sensor and processor are described in U.S. Pat. No. 5,590,649 entitled Apparatus and Method for Measuring an Induced Perturbation to Determine Blood Pressure and an intelligent cuff inflation (ICI) sensor and processor are described in U.S. Pat. No. 5,785,659 entitled Automatically Activated Blood Pressure Measurement Device, both patents incorporated by reference herein.

Advantageously, the multiple parameter processor **500** is responsive to a combination of multiple physiological parameters to indicate sepsis so that an alert can be provided based upon these parameters. Further, the multiple parameter processor **500** responds not only to parameter limits but also to parameter trend information, parameter patterns and parameter variability, so as to reflect a patient condition over

time. In an embodiment, sepsis indicators **254** include alarms and wellness indicators that indicate stages of sepsis from none, to the onset of sepsis, to severe sepsis and septic shock. These outputs, for example, provide a warning of a potential onset of sepsis at an early stage and can trigger alarms as sepsis symptoms progress. Further, drug administration control **256** controls the administration of drugs or alters drug doses in response to patient condition. In an embodiment, the multiple parameter processor **500** compares parameter limits and rising or falling trends of the measurements **234**, **244**, **236**, **238**, **274**, **295** alone or in combination, with corresponding predetermined thresholds and generates indicators and alarms **254** or drug administration controls **256** in response. The comparisons utilize a rule-based metric analysis, as described in detail in respect to FIGS. 4-5, below.

In one embodiment, the sepsis indicators **254** include a green indicator signaling a stable condition, a yellow indicator signaling a less stable condition or a potential sepsis onset and a red indicator signaling an unstable or severe sepsis condition. The indicators **254** may be, for example, various display LEDs emitting wavelengths of the appropriate colors. In an embodiment, a sepsis monitor **400** provides indicators **254** according to TABLES 1 and 2 below.

In an embodiment according to TABLE 1, below, if a patient's pulse rate (PR) and respiration rate (RR) are less than predetermined maximum limits and their body temperature is within a predetermined normal range, then the sepsis monitor **400** displays a green indicator. However, if more than one of pulse rate, respiration rate and body temperature are changing, where applicable changes in pulse rate and respiration rate are rate increases, then the sepsis monitor **400** displays a yellow indicator, signaling a potential onset of sepsis. If more than one of pulse rate, respiration rate and temperature become abnormal, including pulse rate and respiration rate above a predetermined limit and temperature outside of a predetermined range, then the sepsis monitor **400** displays a red indicator, signaling a potential sepsis condition.

TABLE 1

Rule-Based Monitor Outputs	
RULE	OUTPUT
If PR < heart rate limit; RR < breathing rate limit; & T in normal range.	Then illuminate green indicator.
If PR rising > heart rate trend limit; RR rising > breathing rate trend limit; & T rising or fallina.	Then illuminate yellow indicator
If PR > heart rate limit; RR > breathing rate limit; & T outside normal range.	Then illuminate red indicator; Trigger audible alarm.

In an embodiment according to TABLE 2, below, if a patient's carboxyhemoglobin (HbCO), methemoglobin (HbMet) and blood pressure (BP) are normal, i.e. HbCO and HbMet less than predetermined maximum limits and BP greater than a predetermined minimum limit, then the sepsis monitor **400** displays a green indicator. However, if any of HbCO, HbMet and BP are changing, where applicable changes in HbCO and HbMet are increases and the applicable change in BP is a decrease, then the sepsis monitor **400** displays a yellow indicator, signaling a potential onset of sepsis. If any of HbCO, HbMet and BP change beyond

predetermined limits, then the sepsis monitor **400** displays a red indicator, signaling a potential sepsis condition.

TABLE 2

Additional Rule-Based Monitor Outputs	
RULE	OUTPUT
If HbCO < CO limit; HbMet < Met limit; & BP > blood pressure limit.	Then illuminate green indicator.
If HbCO rising > CO trend limit; HbMet rising > Met trend limit or BP falling.	Then illuminate yellow indicator
If HbCO > HbCO limit threshold; HbMet > HbMet limit threshold; or BP < blood pressure limit.	Then trigger an alarm, such as An audible or a visual alert or both.

In other embodiments, a sepsis monitor **400** utilizes predetermined limits and ranges on any or all of PR, RR, T, HbCO, HbMet and BP to indicate no sepsis, a potential onset of sepsis or a sepsis condition, with green, yellow and red indicators or with other visual and audible indicators, displays and alarms. Other indicators, alarms, controls and diagnostics in response to various combinations of parameters and thresholds can be substituted for, or added to, the rule-based outputs illustrated in TABLES 1 and 2.

Other parameter measurements that may be input to the multiple parameter processor **500** include oxygen saturation (SpO₂) and perfusion index (PI) as derived from a pulse oximeter, EGG, EEG and ETCO₂, to name a few. All of these parameters may indicate real-time measurements and historical data such as measurement trends, patterns and variability. Signal quality measurements may also be input to the multiple parameter processor **500**. Pulse oximetry signal quality and data confidence indicators are described in U.S. Pat. No. 6,684,090 entitled Pulse Oximetry Data Confidence Indicator, a pattern recognition alarm indicator is described in U.S. Pat. No. 6,822,564 entitled Parallel Measurement Alarm Processor, both patents assigned to Masimo Corporation, Irvine, Ga. and incorporated by reference herein.

FIG. 3 illustrates a sepsis monitoring system **300** combining a sepsis monitor **400** (FIG. 1) and a drug administration device **204** (FIGS. 2A-B) into a drug infusion monitor **301**. The sepsis monitoring system **300** has an optical sensor **306** and a piezoelectric sensor **316** attached to a patient's body **1**. The optical sensor **306** detects pulsatile blood components and the piezoelectric sensor **316** detects tracheal sounds. The corresponding optical and acoustic sensor signals are transmitted to the drug infusion monitor **301** via an optical-sensor cable **307** and an acoustic-sensor cable **317**. The drug infusion monitor **301** generates blood parameter measurements such as PR, HbCO and HbMet and biological sound measurements such as respiration rate (RR) and processes the measurements to display sepsis indicators and administer corresponding treatments. In a particular embodiment, the drug infusion monitor **301** intravenously administers one or more drugs, such as recombinant activated protein C, to the patient **1** in doses and dose intervals so as to respond to varying stages of sepsis or the potential onset of sepsis and to transitions between less severe and more severe stages of sepsis.

FIG. 4 illustrates a sepsis monitor embodiment **400** having sensor signal processor(s) **401**, a multiple parameter processor **500**, sensor signal inputs **410** to the signal processor(s) **401** and monitor outputs **430** from the parameter processor **500**. Monitor outputs **430** may be sepsis alarms, wellness indicators, controls and sepsis diagnostics. Alarms

may be used to alert medical personnel to a potential urgent or emergency medical condition in a patient under their care. Wellness indicators may be used to inform medical personnel as to patient condition stability or instability, such as a less urgent but potentially deteriorating medical state or condition. Diagnostics may be messages or other indicators used to assist medical personnel in diagnosing or treating a patient condition. Controls may be used to affect the operation of a medical treatment device, as described above, or other medical-related equipment.

In an embodiment, the multiple parameter processor **500** also has an input and output port (I/O) **405** that provides communications to the outside world. The I/O includes user I/O and external device communications to name a few. User I/O allows manual data entry and control. For example, a menu-driven operator display may be provided to allow entry of predetermined alarm thresholds. External device communications may include interfaces, networks or wireless communications to PCs, printers, chart recorders or displays to name a few.

FIG. 5 illustrates a sepsis monitor embodiment **500** having a pre-processor **510**, a metric analyzer **520**, a post-processor **530** and a controller **540**. The pre-processor **510** has inputs **420** that may be real-time physiological parameter measurements, historical physiological parameter measurements, signal quality measures or any combination of the above. The pre-processor **510** generates metrics **512** that may include historical or real-time parameter trends, detected parameter patterns, parameter variability measures and signal quality indicators to name a few. As examples, trend metrics may indicate if a physiological parameter is increasing or decreasing at a certain rate over a certain time, pattern metrics may indicate if a parameter is cyclical within a particular frequency range or over a particular time period, variability metrics may indicate the extent of parameter stability.

As shown in FIG. 5, the metric analyzer **520** is configured to provide test results **522** to the post-processor based upon various rules applied to the metrics **512** in view of various thresholds **524**. As an example, the metric analyzer **520** may output an alarm trigger **522** to the post-processor **530** when a parameter measurement **503** increases faster than a predetermined rate. This may be expressed, as an example, by a rule that states "if trend metric exceeds trend threshold then trigger alarm." TABLE 1 and TABLE 2, above, illustrate sepsis monitor rules applied to metrics including PR, RR, T, HbCO, HbMet and BP parameters and trends.

Also shown in FIG. 5, the post processor **530** inputs test results **522** and generates outputs **502** including alarms, wellness indicators, controls and diagnostics. Alarms may be, for example, audible or visual alerts warning of critical conditions that need immediate attention. Wellness indicators may be audible or visual cues, such as an intermittent, low-volume tone or a red/yellow/green light indicating a patient with a stable or unstable physiological condition, as examples. Controls may be electrical or electronic, wired or wireless or mechanical outputs, to name a few, capable of interfacing with and affecting another device. Diagnostics may indicate a particular patient condition, such as the potential onset of sepsis.

Further shown in FIG. 5, the controller **540** interfaces with I/O **509**. In one embodiment, the I/O **509** provides predetermined thresholds, which the controller **540** transmits to the metric analyzer **520**. The controller **540** may also define metrics **514** for the pre-processor **510** and define outputs **534** for the post-processor **530**.

A sepsis monitor has been disclosed in detail in connection with various embodiments. These embodiments are disclosed by way of examples only and are not to limit the scope of the claims that follow. One of ordinary skill in art will appreciate many variations and modifications.

What is claimed is:

1. A patient monitoring method for non-invasively determining whether a patient is experiencing a potential sepsis condition, said method comprising:

receiving a plurality of noninvasively generated sensor signals responsive to physiological parameters indicative of an onset of a sepsis condition in said patient, at least one of said sensor signals responsive to the output of a noninvasive optical sensor, said output responsive to attenuation of light by body tissue of said patient at a measurement site;

electronically computing with a signal processor measurements for said physiological parameters from the sensor signals, said physiological parameters including at least carboxyhemoglobin, methemoglobin, and blood pressure;

electronically applying with said signal processor a plurality of predetermined rules to the physiological parameters to determine an onset of a sepsis condition, said plurality of predetermined rules including evaluating relationships between trends of each parameter in said physiological parameters; and

indicating to an observer the potential existence of the sepsis condition responsive to said applying said rules.

2. The sepsis monitoring method according to claim 1 further comprising outputting a control signal from said multiple parameter processor to a drug administration device configured to intravenously supply fluids to said patient, said control signal including information configured to cause said drug administration device to alter administration of fluids in response to a determined sepsis condition.

3. A method of electronically monitoring signals indicative of a patient condition to determine when to warn a caregiver that said patient condition is indicative of sepsis, the method comprising:

outputting a first signal from a noninvasive optical sensor indicative of an absorption of light by body tissue of said patient;

outputting a second signal from one of (i) a noninvasive acoustic sensor applied to an area of skin around a patient's throat where said second signal is indicative of acoustically sensed tracheal sounds or (ii) a noninvasive blood pressure cuff device;

receiving said first signal, said second signal, and a plurality of noninvasively generated other signals, said first signal, said second signal, and said other signals responsive to physiological parameters of said patient;

electronically processing said first, second and said other signals to output first measurement values for said physiological parameters including at least pulse rate, respiration rate, temperature, and oxygen saturation and electronically processing said first, second and said other signals to output second measurement values for said physiological parameters including at least carboxyhemoglobin, methemoglobin, blood pressure and oxygen saturation;

electronically applying with a processor a plurality of predetermined rules to at least said carboxyhemoglobin, methemoglobin, and blood pressure of said second measurement values, said plurality of predetermined

rules including evaluating relationships between trends of at least carboxyhemoglobin, methemoglobin, and blood pressure; and
when said application of said rules indicates said patient condition is indicative of sepsis, outputting at least one 5
of an audio or visual indication to said caregiver that a potential for sepsis exists.

4. The method according to claim 3, further comprising sending a control signal to a drug administration device intravenously in communications with said patient, said 10
control signal responsive to said indication of said sepsis, said device providing treatment for said sepsis.

* * * * *

专利名称(译)	败血症监测		
公开(公告)号	US10226576	公开(公告)日	2019-03-12
申请号	US14/191925	申请日	2014-02-27
[标]申请(专利权)人(译)	CERCACOR LAB		
申请(专利权)人(译)	CERCACOR LABORATORIES , INC.		
当前申请(专利权)人(译)	Masimo公司		
[标]发明人	KIANI MASSI E		
发明人	KIANI, MASSI E.		
IPC分类号	A61B7/00 A61B5/0205 A61M5/172 A61B5/022 A61B5/08 A61B5/1455 A61B5/00 A61B7/04 A61B5/0245		
CPC分类号	A61M5/1723 A61B5/022 A61B5/0205 A61B5/02455 A61B5/08 A61B5/412 A61B5/6826 A61B5/6838 A61B7/04 A61B5/14551 A61B2560/0276 A61B5/082		
优先权	60/800629 2006-05-15 US		
其他公开文献	US20140180038A1		
外部链接	Espacenet		

摘要(译)

传感器连接到生物上以产生相应的传感器信号。监视器与传感器通信，以便响应传感器信号导出生理参数。将预定限制应用于生理参数。响应于生理参数和预定限制的至少一个指示器指示生物体中败血症状况的发作。

